Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Melanoma Clinical Trials

106 recruiting trials for Melanoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
106
Total Trials
106
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03702309

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor...

Sponsor: University Health Network, TorontoEnrolling: 25001 location
RECRUITINGNCT07042243

The Florida ASCENT Study

The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with cancer. The main...

Sponsor: University of FloridaEnrolling: 1001 location
RECRUITINGNCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior...

Sponsor: AstraZenecaEnrolling: 10017 locations
RECRUITINGPhase 2NCT05229614

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials....

Sponsor: CNAO National Center of Oncological HadrontherapyEnrolling: 274 locations
RECRUITINGNCT05539677

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors...

Sponsor: N.N. Petrov National Medical Research Center of OncologyEnrolling: 10001 location
RECRUITINGPhase 1NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With...

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in...

Sponsor: Genentech, Inc.Enrolling: 45020 locations
RECRUITINGPhase 1NCT06596915

Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in...

Sponsor: Shandong Boan Biotechnology Co., LtdEnrolling: 1671 location
RECRUITINGPhase 1 / Phase 2NCT00722228

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her...

Sponsor: Hadassah Medical OrganizationEnrolling: 501 location
RECRUITINGNCT03605771

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

This is an observational, multicentre epidemiological study with a longitudinal cohort in which information will be retrieved from medical records of patients with advanced...

Sponsor: Grupo Español Multidisciplinar de MelanomaEnrolling: 40020 locations
RECRUITINGPhase 2NCT05512481

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.

Sponsor: Peking University Cancer Hospital & InstituteEnrolling: 601 location
RECRUITINGPhase 2NCT06121180

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 324 locations
RECRUITINGNCT05478876

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract

The present monocentric prospective phase 2 study aims to reproduce the results obtained at NIRS thus offering the possibility of obtaining a promising rate of progression-free...

Sponsor: CNAO National Center of Oncological HadrontherapyEnrolling: 91 location
RECRUITINGPhase 1 / Phase 2NCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma...

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: *...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 37017 locations
RECRUITINGPhase 2NCT07072728

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for?...

Sponsor: Psyence Australia Pty LtdEnrolling: 873 locations
RECRUITINGPhase 2NCT06623461

LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota...

Sponsor: Canadian Cancer Trials GroupEnrolling: 12814 locations
RECRUITINGPhase 1 / Phase 2NCT01898039

Modified Vaccine for High Risk or Low Residual Melanoma Patients

This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very...

Sponsor: Hadassah Medical OrganizationEnrolling: 501 location
RECRUITINGPhase 1 / Phase 2NCT07280832

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety,...

Sponsor: Shanghai JMT-Bio Inc.Enrolling: 1881 location
RECRUITINGPhase 2NCT06414590

Neoadjuvant Tebentafusp for Uveal Melanoma

This is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma. Patients must be...

Sponsor: Thomas Jefferson UniversityEnrolling: 192 locations
RECRUITINGPhase 1NCT05130255

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step...

Sponsor: Y-mAbs TherapeuticsEnrolling: 608 locations
RECRUITINGNCT04272658

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic...

Sponsor: University Hospital, BrestEnrolling: 561 location
RECRUITINGNCT04611568

War on Melanoma™ Public Health & Education Campaign

This trial studies how well a health educational campaign works in increasing early detection of melanoma in Oregon. The health educational campaign may provide information to...

Sponsor: OHSU Knight Cancer InstituteEnrolling: 750001 location
RECRUITINGPhase 3NCT02000089

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for...

Sponsor: Johns Hopkins UniversityEnrolling: 90009 locations
RECRUITINGPhase 1 / Phase 2NCT06359860

A Study of ST-1898 for Unresectable or Metastatic Melanoma

ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc. This trial is to evaluate its safety,...

Sponsor: Beijing Scitech-Mq Pharmaceuticals LimitedEnrolling: 641 location
RECRUITINGNCT03888950

Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy

The objective of this study is to assess whether FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET-CT could be an early predictive method of therapeutic response to...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 201 location
RECRUITINGPhase 2NCT06712927

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.

Sponsor: Stanford UniversityEnrolling: 601 location
RECRUITINGNCT06899789

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

This is a multicentric, observational study, including all European centres willing to take part. The multicentre nature is necessary for enhancing the generalisability of our...

Sponsor: Fondazione IRCCS Policlinico San Matteo di PaviaEnrolling: 2501 location
RECRUITINGPhase 1NCT06545682

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 501 location
RECRUITINGPhase 2NCT06319196

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition...

Sponsor: University Health Network, TorontoEnrolling: 541 location
RECRUITINGNCT06675643

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary...

Sponsor: Mayo ClinicEnrolling: 1001 location
RECRUITINGNCT07469709

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before...

Sponsor: Fondazione del Piemonte per l'OncologiaEnrolling: 8501 location
RECRUITINGPhase 2NCT06330064

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic...

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell...

Sponsor: Daiichi SankyoEnrolling: 52020 locations
RECRUITINGPhase 3NCT06007690

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011)...

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or...

Sponsor: Aura BiosciencesEnrolling: 10020 locations
RECRUITINGPhase 3NCT02821013

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking...

Sponsor: Canadian Cancer Trials GroupEnrolling: 61420 locations
RECRUITINGNCT06605404

Pan-tumor MRD Study

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage...

Sponsor: Paradigm HealthEnrolling: 13502 locations
RECRUITINGNCT06602648

MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)

The aim of this study is to investigate a type of skin cancer, also known as melanoma, in children, adolescents, and young adults, who will be referred to as CAYA patients in this...

Sponsor: University of FlorenceEnrolling: 1001 location
RECRUITINGNCT03116412

A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma

It is not known whether radiological assessments during follow up after surgery for high risk melanoma improve survival. Since radiological examinations are resource demanding,...

Sponsor: Uppsala UniversityEnrolling: 130020 locations
RECRUITINGPhase 2 / Phase 3NCT06697301

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With...

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Sponsor: Eikon TherapeuticsEnrolling: 74020 locations
RECRUITINGNCT04986748

Using QPOP to Predict Treatment for Sarcomas and Melanomas

This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples....

Sponsor: National Cancer Centre, SingaporeEnrolling: 1001 location
RECRUITINGNCT06391099

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic...

This phase I trial studies how well a ketogenic dietary intervention works to improve response to immunotherapy in patients with melanoma and kidney cancer that has spread from...

Sponsor: Ohio State University Comprehensive Cancer CenterEnrolling: 601 location
RECRUITINGPhase 1NCT06204991

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

The primary objective of this Phase 1 clinical trial is to evaluate the feasibility and tolerability of a novel generation of gene-modified tumor infiltrating lymphocytes (TILs)...

Sponsor: Inge Marie SvaneEnrolling: 102 locations
RECRUITINGPhase 1 / Phase 2NCT06814496

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with...

Sponsor: University of ArizonaEnrolling: 302 locations
RECRUITINGNCT06075524

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types....

Sponsor: Mayo ClinicEnrolling: 5001 location
RECRUITINGPhase 2NCT05969860

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to...

Sponsor: Mayo ClinicEnrolling: 2202 locations
RECRUITINGNCT05649683

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors

Checkpoint inhibitor such as anti-CTLA-4 and anti-PD-1 are known to block inhibitory signals and increase the immune antimutoral response. Nivolumab and Ipilimumab association is...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 603 locations
RECRUITINGPhase 1NCT07562841

Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy

Advanced melanoma is a highly aggressive malignancy that frequently exhibits resistance to conventional radiotherapy and single-agent immunotherapy. This study aims to evaluate...

Sponsor: West China HospitalEnrolling: 62 locations
RECRUITINGPhase 2NCT06627244

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal...

Sponsor: University of MiamiEnrolling: 301 location
RECRUITINGNCT01980264

Harmonics-based in Vivo Optical Virtual Biopsy

The research aims to study the molecules and structures in human skin by the image formation of harmonic-based in vivo optical virtual biopsy.

Sponsor: National Taiwan University HospitalEnrolling: 5001 location
RECRUITINGPhase 2NCT05546827

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
RECRUITINGPhase 3NCT07381972

Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma

Evaluation of a therapeutic protocol based on the combination of photodynamic therapy and sonodynamic therapy, referred to as sonophotodynamic therapy. Since this new protocol is...

Sponsor: University of Sao PauloEnrolling: 1421 location
RECRUITINGPhase 2NCT07215182

[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

The goal of this clinical trial is to investigate the use of the tracer \[68Ga\]Ga-FAPI-46 for PET/CT-imaging in response evaluation of patients with advanced stage malignant...

Sponsor: Barbara Malene FischerEnrolling: 202 locations

Showing 50 of 106 trials.Search all Melanoma trials

Frequently Asked Questions

There are currently 106 clinical trials for Melanoma, with 106 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Melanoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Melanoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.